Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, Oct. 5, 2020 at 8:00 a.m. ET.

Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its public offering of 5,000,000 shares of common stock at a public offering price of $23.50 per share. All of the shares are being offered by Beam Therapeutics. In addition, Beam Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.

Beam Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept.  28, 2020  (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines though base-editing, announced today the commencement of a proposed public offering of 4,500,000 shares of its common stock. All of the shares will be offered by Beam. Beam also expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock.

Beam Therapeutics Announces Proposed Public Offering of Common Stock

Editas Medicine

A rumored merger has investors excited, although details are scarce.

Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher on Wednesday after William Blair initiated coverage on the company's stock with an Outperform rating and announced a $33 price target.

Why Beam Therapeutics Is Trading Higher Today

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics

CAMBRIDGE, Mass., July  30, 2020  (GLOBE NEWSWIRE) --  Beam Therapeutics Inc.  (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following August investor conferences:

Beam Therapeutics to Participate in Upcoming Investor Conferences 

Shares of a Cambridge, Massachusetts-based biotechnology company that is taking a different approach to gene editing have gained more than 25% since its early February initial public offering.

Beam Therapeutics Taking Novel Approach to Gene Therapy

Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo

Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results

Successful Initial Public Offering Completed and Continued Advancement of Broad Portfolio of Novel Base Editing Programs Successful Initial Public Offering Completed and Continued Advancement of Broad Portfolio of Novel Base Editing Programs

Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results

CAMBRIDGE, Mass., March  16, 2020  (GLOBE NEWSWIRE) --  Beam Therapeutics Inc.  (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key leadership appointments, including the promotion of Manmohan Singh, Ph.D., from vice president to senior vice president of pharmaceutical sciences and delivery technologies, and the appointment of Christine Swenson as senior vice president of regulatory affairs.

Beam Therapeutics Announces Key R&D Appointments

Beam Therapeutics Inc. (NASDAQ: BEAM) is not exactly a household name in corporate America.

Beam Therapeutics Could See Over 40% Upside Despite Unlucky IPO Timing

Beam Therapeutics' new approach offers more precision than CRISPR.

Gene-Editing IPO Gets Warm Reception From Investors

News for Beam Therapeutics Stock (BEAM)